RecruitingPhase 2

A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin

United States100 participantsStarted 2025-10-13

Plain-language summary

The purpose of this study is to see how well LY3938577 works and how safe it is compared to degludec in people with type 2 diabetes. Participation in the study will last about 26 weeks.

Who can participate

Age range18 Years – 70 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Have type 2 diabetes * Are receiving ≥20 units of basal insulin per day and ≤55 units/day and ≤1.5 units/kg/day at screening * Have hemoglobin A1c (HbA1c) 7.5% to 10.5% inclusive * Have a body mass index (BMI) of 20 or higher and less than 35 kilograms per square meter (kg/m2) Exclusion Criteria: * Have type 1 diabetes

What they're measuring

Change from Baseline in Glucose Time in Range Between 70 and 180 mg/dL Inclusive (Non-Inferiority Analysis)

Timeframe: Baseline through Week 20

Trial details

NCT IDNCT07215312

SponsorEli Lilly and Company

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2026-11

Contact for this trial

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or

317-615-4559 LillyTrials@Lilly.com

View on ClinicalTrials.gov More Diabetes Mellitus, Type 2 trials